X4 Pharmaceuticals Investor Event
About The Event
Join us for a virtual X4 Pharmaceuticals investor event / presentation of new clinical data from the pivotal Phase 3 trial of mavorixafor in people with WHIM syndrome, a rare, combined immunodeficiency.
New data to be presented by X4 will focus on additional secondary endpoints, including the impact of oral, once-daily mavorixafor on the rate, severity, and duration of infections, which are often the most burdensome clinical symptoms in individuals with WHIM syndrome and those with chronic neutropenic disorders.
The event will also feature commentary from multiple clinical experts in immunology and hematology and several WHIM patients, who will discuss the current treatment landscape and unmet medical needs.
A live question and answer session will follow the formal presentations.